In focus · trending topic

Lebers congenital amaurosis

18 stories · following the connections

ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10

By Nasdaq OMXMay 31, 2017, 11:08 AM UTC

ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10

By Nasdaq OMXMay 31, 2017, 11:08 AM UTC

ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10

By Nasdaq OMXMay 31, 2017, 11:08 AM UTC

ProQR Receives Fast Track Designation from the FDA for QR-110 for Leber’s Congenital Amaurosis Type 10

By Nasdaq OMXMay 31, 2017, 11:08 AM UTC

ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome

By Nasdaq OMXMay 1, 2017, 11:01 AM UTC

ProQR to Present its Ophthalmology Pipeline at ARVO, Highlighting Programs in Leber’s Congenital Amaurosis Type 10 (LCA 10) and Usher Syndrome

By Nasdaq OMXMay 1, 2017, 11:01 AM UTC

ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients

By Nasdaq OMXApr 27, 2017, 11:03 AM UTC

ProQR Announces Clearance of IND Application to Start Clinical Trial for QR-110 in Leber’s Congenital Amaurosis Type 10 Patients

By Nasdaq OMXApr 27, 2017, 11:03 AM UTC